Karyopharm Therapeutics Pipeline & Clinical Trials

SELINEXOR

Description	Phase 1	Phase 2	Phase 3	Market Approval
Multiple myeloma (penta-refractory) STORM¹^,² \| + dexamethasone	Phase 1	Phase 2	Phase 3	Market Approval
Multiple myeloma (2L+) BOSTON¹^,³ \| + bortezomib and dexamethasone	Phase 1	Phase 2	Phase 3	Market Approval
Diffuse large B cell lymphoma (relapsed/refractory) SADAL¹^,⁴^,^a \| monotherapy	Phase 1	Phase 2	Phase 3	Market Approval
Multiple myeloma (2L+; post anti-CD38) XPORT-MM-031⁵^,^b^,^c \| + pomalidomide and dexamethasone View Clinical Trial Resource	Phase 1	Phase 2	Phase 3	Market Approval
Myelofibrosis (JAKi treatment-naïve) SENTRY⁶ \| + ruxolitinib View Clinical Trial Resource	Phase 1	Phase 2	Phase 3	Market Approval
Endometrial cancer (maintenance therapy; TP53 wild-type) XPORT-EC⁷ \| monotherapy View Clinical Trial Resource	Phase 1	Phase 2	Phase 3	Market Approval
Endometrial Cancer (maintenance therapy) SIENDO⁸ \| monotherapy	Phase 1	Phase 2	Phase 3	Market Approval
Diffuse large B cell lymphoma (relapsed/refractory) XPORT-DLBCL-30⁹^,^d \| + ruxolitinib, gemcitabine, cisplatin, dexamethasone	Phase 1	Phase 2	Phase 3	Market Approval
Myelofibrosis (JAKi treatment-naïve; moderate thrombocytopenia) SENTRY-2¹⁰ \| monotherapy View Clinical Trial Resource	Phase 1	Phase 2	Phase 3	Market Approval
Multiple myeloma (relapsed/refractory and frontline) STOMP¹¹^,^e \| multiple agents View Clinical Trial Resource	Phase 1	Phase 2	Phase 3	Market Approval

ELTANEXOR

Description	Phase 1	Phase 2	Phase 3	Market Approval
Myelodysplastic neoplasms (relapsed/refractory) KCP-8602-801¹² \| monotherapy	Phase 1	Phase 2	Phase 3	Market Approval

Hematologic Malignancies

Solid Tumors

*Pipeline includes completed trials and trials in progress (last updated May 1, 2024). ᵃThis indication is approved under accelerated approval based on response rate. Continued approval may be contingent on confirmatory trial(s). ᵇSponsored by European Myeloma Network; EMN29. ᶜVersus elotuzumab, pomalidomide, and dexamethasone. dXPORT-DLBCL-030 is a Phase 2/3 study. eSTOMP has a total of 12 arms; enrolling arm 12 only.

1. XPOVIO (selinexor) [package insert]. Newton, MA; Karyopharm Therapeutics. 2. ClinicalTrials.gov identifier: NCT02336815. https://clinicaltrials.gov/ct2/show/study/NCT02336815. Accessed May 1, 2024.
3. ClinicalTrials.gov identifier: NCT03110562. https://clinicaltrials.gov/ct2/show/study/NCT03110562. Accessed May 1, 2024. 4. ClinicalTrials.gov identifier: NCT02227251. https://clinicaltrials.gov/ct2/show/study/NCT02227251. Accessed May 1, 2024. 5. ClinicalTrials.gov identifier: NCT05028348. https://clinicaltrials.gov/ct2/show/study/NCT05028348. Accessed May 1, 2024.
6. ClinicalTrials.gov identifier: NCT04562389. https://clinicaltrials.gov/ct2/show/study/NCT04562389. Accessed May 1, 2024. 7. ClinicalTrials.gov identifier: NCT05611931. https://clinicaltrials.gov/ct2/show/study/NCT05611931. Accessed May 1, 2024. 8. ClinicalTrials.gov identifier: NCT03555422. https://clinicaltrials.gov/ct2/show/study/NCT03555422. Accessed May 1, 2024.
9. ClinicalTrials.gov identifier: NCT04442022. https://clinicaltrials.gov/ct2/show/study/NCT04442022. Accessed May 1, 2024. 10. ClinicalTrials.gov identifier: NCT05980806. https://clinicaltrials.gov/ct2/show/study/NCT05980806. Accessed May 1, 2024. 11. ClinicalTrials.gov identifier: NCT02343042. https://clinicaltrials.gov/ct2/show/study/NCT02343042. Accessed May 1, 2024. 12. ClinicalTrials.gov identifier: NCT02649790. https://clinicaltrials.gov/ct2/show/study/NCT02649790. Accessed May 1, 2024.

Clinical Trials

Find more information about ongoing clinical trials evaluating Karyopharm’s investigational medicines.

Learn More